High Throughput Screening (HTS)

High Throughput Screening (HTS) Market Outlook

The global High Throughput Screening (HTS) market is projected to reach $XX billion by 2035, with a compound annual growth rate (CAGR) of XX% during the forecast period of 2025-2035. The rise of personalized medicine, the need for accelerating drug discovery, and advancements in technology are major growth factors driving the HTS market forward. Additionally, the increasing adoption of automation and robotics within laboratory workflows is expected to enhance the efficiency of screening processes, thereby propelling market growth. The integration of artificial intelligence and machine learning in HTS systems is also contributing to improved data analysis and predictive modeling capabilities. The growing number of pharmaceutical companies focusing on research and development, particularly in oncology and rare diseases, is anticipated to further stimulate the demand for HTS solutions.

Growth Factor of the Market

Several key factors are contributing to the growth of the high throughput screening market. Firstly, the accelerated pace of drug discovery processes across pharmaceutical and biotechnology sectors is pushing organizations to adopt HTS technologies, allowing them to evaluate thousands of compounds simultaneously. Moreover, advancements in technology, such as the integration of artificial intelligence and machine learning algorithms, are revolutionizing data analysis and interpretation in HTS, leading to more accurate results and faster decision-making. The increasing prevalence of chronic diseases has sparked a demand for innovative drug discovery methods to identify novel therapeutic candidates quickly. Furthermore, the growing number of collaborations between academic institutions and industry stakeholders is fostering research and development activities, thereby expanding the application scope of HTS technologies in various fields. Lastly, government initiatives and funding aimed at promoting biomedical research are also playing a crucial role in boosting the HTS market.

Key Highlights of the Market

• Significant growth in demand for drug discovery and development processes.
• Rapid technological advancements leading to improved HTS methodologies.
• Increasing collaboration between academia and pharmaceutical industries.
• Rising prevalence of chronic diseases driving the need for novel therapeutic solutions.
• Enhanced data analytics capabilities through AI and machine learning integration.

By Technology

Label-Free Technology:

Label-free technology is a burgeoning segment within the HTS market, allowing researchers to assess biological interactions without the need for fluorescent or radioactive labels. This technology enhances the accuracy of assays by preserving the native state of the biomolecules and enabling real-time monitoring of interactions. The increased demand for more precise screening methods in drug discovery is propelling the adoption of label-free technology, especially in the fields of target identification and validation. Additionally, label-free platforms facilitate high-throughput workflows, enabling researchers to quickly analyze large datasets and generate actionable insights, thereby driving innovation in therapeutic development.

Cell-Based Assays:

Cell-based assays are vital in the HTS market as they provide a more physiologically relevant environment for assessing drug efficacy and toxicity compared to traditional biochemical assays. These assays allow for the evaluation of cellular responses to compounds, thus offering insights into the pharmacodynamic properties of new drugs. The growing trend towards personalized medicine has increased the demand for cell-based assays, as they can be tailored to reflect individual patient profiles. Furthermore, advancements in stem cell technology and 3D cell cultures are enhancing the capabilities of cell-based assays, making them essential tools for modern drug development processes.

Ultra High-Throughput Screening:

Ultra high-throughput screening (UHTS) represents the next evolution in HTS technologies, enabling the screening of millions of compounds in a single experiment. This technology utilizes advanced robotics and automation to facilitate rapid sample processing and data acquisition, significantly reducing the time required for drug discovery. The increasing complexity of biological systems and the need for comprehensive datasets are driving the growth of UHTS. With its ability to provide expansive data on compound interactions and biological responses, UHTS is becoming a critical component of modern drug discovery pipelines, particularly in the search for novel therapeutics in oncology and infectious diseases.

Lab-On-A-Chip Technology:

Lab-on-a-chip technology is gaining traction in the HTS market as it miniaturizes laboratory processes onto a single chip, allowing for rapid analysis and reduced reagent consumption. This technology enhances the efficiency of screening procedures by integrating multiple laboratory functions into a compact format. The benefits of lab-on-a-chip systems include faster assay times, lower costs, and improved accuracy in results. As researchers seek to streamline workflows and enhance throughput, lab-on-a-chip technology is becoming increasingly vital in pharmaceutical and biotechnology research, particularly for applications such as toxicology testing and biomarker discovery.

Others:

This category includes various emerging technologies that contribute to the HTS market but do not fall under the primary classifications mentioned above. Technologies such as microfluidics, 3D bioprinting, and CRISPR-based screening are gaining importance as they offer unique advantages for specific applications. The diversity of these technologies allows researchers to tailor their screening approaches, leading to increased efficiency and innovation in drug development. As the landscape of HTS evolves, these novel methods will likely play a significant role in shaping future research directions and improving therapeutic outcomes.

By Application

Drug Discovery:

Drug discovery is one of the most significant applications of high throughput screening technologies. In this segment, HTS is employed to identify potential drug candidates from vast compound libraries, facilitating the evaluation of their pharmacological properties. The increasing focus on discovering novel therapeutics to combat diseases such as cancer and neurodegenerative disorders is driving the growth of this application segment. Pharmaceutical companies are investing heavily in HTS technologies to accelerate their drug development processes and streamline their research efforts, thus reducing the time and costs associated with bringing new drugs to market.

Toxicology Assessment:

Toxicology assessment is a crucial application of HTS that involves evaluating the safety and potential adverse effects of chemical compounds on biological systems. HTS technologies enable researchers to conduct large-scale toxicity screens efficiently, identifying hazardous compounds early in the drug development process. With regulatory agencies emphasizing the importance of thorough toxicological evaluations, the demand for HTS in this domain is expected to rise significantly. The integration of advanced assays and predictive modeling techniques is further enhancing the capabilities of toxicology assessment, allowing for a more comprehensive understanding of compound safety profiles.

Chemical Biology:

In the field of chemical biology, HTS plays a pivotal role in elucidating the mechanisms of action of bioactive compounds and their interactions with biological targets. Researchers utilize HTS to screen libraries of small molecules against specific targets, helping to discover new probes and tools for studying biological processes. The synergy between chemical biology and HTS is driving innovation in target validation and therapeutic discovery, particularly in the areas of cancer and infectious diseases. The ability to rapidly identify and characterize novel compounds is essential for advancing our understanding of complex biological systems.

Biochemical Screening:

Biochemical screening is an integral application of HTS focused on evaluating the activity of compounds against biomolecules, such as enzymes and receptors. This application is essential for identifying lead candidates in drug discovery and understanding the biological relevance of various interactions. The increasing demand for efficient screening methodologies is pushing the adoption of HTS technologies in biochemical screening, allowing researchers to conduct large-scale assays with high precision. As the field continues to evolve, biochemical screening will remain a crucial component of modern drug discovery efforts, particularly as the search for targeted therapies intensifies.

Others:

This segment encompasses a range of additional applications where high throughput screening technologies are utilized, including biomarker discovery, environmental testing, and agricultural research. As the versatility of HTS technologies expands, they are being adapted for various fields beyond traditional drug discovery. The ability to screen large libraries of compounds in diverse contexts is opening up new avenues for research and innovation, highlighting the potential for HTS to impact multiple industries. Future developments in HTS applications will likely lead to more interdisciplinary collaboration and broaden the scope of research efforts across various sectors.

By End User

Pharmaceutical and Biotechnology Companies:

Pharmaceutical and biotechnology companies are the primary end users of high throughput screening technologies, leveraging these tools to enhance their drug discovery and development processes. These organizations invest significantly in HTS systems to streamline research workflows, reduce time to market, and improve the chances of successful therapeutic outcomes. With a growing emphasis on personalized medicine, pharmaceutical companies are increasingly utilizing HTS to identify compounds that can be tailored to individual patient needs. The competitive landscape in the biopharmaceutical sector drives companies to adopt advanced HTS technologies to stay ahead in the race for innovative therapies.

Contract Research Organizations:

Contract research organizations (CROs) are vital players in the HTS market, providing specialized services to pharmaceutical and biotechnology companies. These organizations utilize advanced HTS technologies to conduct screening assays on behalf of their clients, enabling them to access cutting-edge methodologies without the need for in-house infrastructure. The demand for outsourced research services is growing, driven by the need for cost-effective and efficient solutions in drug development. CROs are continuously investing in advancing their HTS capabilities to meet the evolving needs of clients and offer comprehensive screening services across various therapeutic areas.

Academic and Research Institutes:

Academic and research institutes play a significant role in the high throughput screening market, utilizing HTS technologies to conduct fundamental research and advance scientific knowledge. These institutions often focus on early-stage drug discovery, target validation, and biomarker identification, contributing to the broader understanding of biological processes. With increasing collaboration between academia and the pharmaceutical industry, research institutes are gaining access to advanced HTS technologies, enabling them to conduct high-quality research. The growth of grant funding and public-private partnerships is also facilitating the adoption of HTS in academic settings, further driving innovation in drug discovery.

Others:

This segment includes various other end users of high throughput screening technologies, such as governmental research institutions, environmental agencies, and agricultural companies. These organizations utilize HTS for diverse applications, including toxicological testing, environmental monitoring, and crop improvement. The versatility of HTS technologies makes them valuable tools for a wide range of research and development activities beyond traditional pharmaceutical applications. As the demand for innovative solutions in various sectors continues to rise, the adoption of HTS technologies is expected to expand across different industries and research fields.

By Product

Instruments:

The instruments segment is a critical component of the high throughput screening market, comprising various devices used in screening assays, such as automated liquid handling systems, microplate readers, and robotic workstations. These instruments play a vital role in enhancing the efficiency and accuracy of HTS processes by automating sample processing and data acquisition. The growing need for rapid and reproducible results in drug discovery is driving investment in advanced HTS instruments, enabling researchers to screen large compound libraries effectively. As technology continues to evolve, the demand for innovative and high-performance instruments is expected to grow, further supporting the advancement of the HTS market.

Reagents & Kits:

Reagents and kits are essential products in the HTS market, providing the necessary components for conducting various assays. This segment includes a wide range of reagents, such as enzymes, substrates, and detection reagents, as well as pre-packaged assay kits designed for specific applications. The increasing complexity of screening assays and the demand for standardized protocols are driving the growth of this segment. Researchers are seeking reliable and high-quality reagents to ensure consistent results, leading to an increased focus on product development and innovation in the reagents and kits sector. As the HTS market expands, the demand for specialized reagents and kits is anticipated to rise significantly.

Consumables:

Consumables, including microplates, pipette tips, and assay plates, are integral to high throughput screening operations. The growth of the HTS market is closely tied to the demand for consumables, as they are essential for conducting assays and managing sample workflows. As the number of screening assays performed in laboratories increases, the need for consumables is also expected to rise. Manufacturers are focusing on developing high-quality, cost-effective consumables that meet the evolving needs of researchers while ensuring compatibility with advanced HTS instruments. This segment is likely to experience steady growth as the HTS market continues to expand.

Software:

Software solutions are critical to the high throughput screening market, providing essential tools for data management, analysis, and visualization. These software platforms enable researchers to efficiently manage large datasets generated during screening assays, facilitating informed decision-making and improving workflow efficiency. The increasing complexity of biological data and the need for sophisticated analytics tools are driving the demand for advanced software solutions in HTS. As organizations seek to leverage data-driven insights to enhance drug discovery processes, the adoption of innovative software technologies is expected to grow, further supporting the HTS market's expansion.

Services:

Services offered within the high throughput screening market encompass a range of support options, including assay development, screening services, and consulting. These services are essential for organizations looking to implement HTS technologies effectively without the need for significant upfront investment in infrastructure. The growing trend towards outsourcing research and development activities is propelling the demand for HTS services, as organizations seek to access specialized expertise and cutting-edge technologies. As the HTS market continues to evolve, service providers are expected to develop tailored solutions to meet the diverse needs of their clients, driving growth in this segment.

By Region

North America is currently the largest market for high throughput screening technologies, accounting for approximately XX% of the global market share. The region's robust pharmaceutical and biotechnology industries, coupled with significant investments in research and development, are driving the growth of HTS in this area. Additionally, the increasing prevalence of chronic diseases and the rising focus on personalized medicine are further propelling the demand for innovative drug discovery methods. The CAGR for the North American HTS market is projected to be XX% during the forecast period, driven by advancements in technology and the growing emphasis on efficient drug discovery processes.

Europe is also a significant region in the high throughput screening market, representing around XX% of the global market share. The region benefits from a strong academic research base, numerous collaborations between industry and academia, and a growing number of biotechnology startups focusing on drug discovery. The increasing emphasis on innovative therapeutic solutions and the ongoing efforts to streamline research workflows are expected to boost the HTS market in Europe. The CAGR for the European HTS market is estimated to be XX%, reflecting the continued growth and adoption of advanced screening technologies across the region.

Opportunities

The high throughput screening market presents numerous opportunities for growth and innovation, particularly as researchers seek to address pressing challenges in drug discovery and development. One significant opportunity lies in the integration of artificial intelligence and machine learning into HTS processes. These technologies can enhance data analysis, enabling researchers to extract valuable insights from large datasets more efficiently. The ability to predict compound interactions and biological responses through advanced analytics can significantly accelerate the drug discovery process, leading to more effective therapeutic candidates. As organizations increasingly embrace data-driven approaches, the demand for AI-powered HTS solutions is expected to rise, creating new avenues for market expansion.

Another promising opportunity within the HTS market is the increasing focus on personalized medicine. As healthcare shifts towards more tailored treatment approaches, there is a growing demand for innovative screening technologies that can identify patient-specific therapeutic candidates. HTS technologies can facilitate the rapid screening of compounds against patient-derived samples, enabling researchers to discover targeted therapies that align with individual patient profiles. This personalized approach not only enhances patient outcomes but also presents significant market potential as organizations strive to develop more effective and customized treatment options. The convergence of HTS with personalized medicine is likely to drive further advancements in the field and expand the overall market landscape.

Threats

The high throughput screening market is not without its challenges, as various threats could impede growth and development. One of the primary threats is the increasing complexity of biological systems, which can complicate the screening processes and lead to ambiguous results. As researchers aim to identify novel therapeutic candidates, the intricate interactions within biological systems may result in unexpected outcomes during screening assays. This complexity can hinder the reliability of HTS technologies and may necessitate the development of more sophisticated methodologies to ensure accurate results. Moreover, the rising costs associated with advanced HTS technologies and the need for continuous upgrades may pose significant challenges for smaller organizations and research institutes, limiting their ability to compete effectively within the market.

Additionally, regulatory hurdles can present substantial challenges for the growth of the HTS market. As the demand for safety and efficacy data increases, researchers must navigate an increasingly stringent regulatory landscape when conducting screening assays. Compliance with regulatory requirements can add complexity to the drug discovery process and may slow down the adoption of HTS technologies. Organizations must invest time and resources to ensure that their screening methodologies meet regulatory standards, which can be a daunting task for those without adequate expertise. The interplay between regulatory challenges and technological advancements will be crucial in shaping the future of the HTS market.

Competitor Outlook

• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche AG
• Merck KGaA
• BD Biosciences
• Sartorius AG
• HighRes Biosolutions, Inc.
• Lonza Group AG
• Corning Incorporated
• Epic Sciences, Inc.
• Charles River Laboratories International, Inc.
• DiscoverX Corporation
• Bio-Rad Laboratories, Inc.
• Biotechne Corporation

The competitive landscape of the high throughput screening market is characterized by a diverse range of companies that offer innovative solutions and technologies to meet the growing demands of drug discovery and development. Major players in the HTS market are focusing on expanding their product portfolios, enhancing technological capabilities, and forming strategic partnerships to maintain a competitive edge. The increasing emphasis on automation and the integration of advanced data analytics in HTS processes are driving companies to invest in research and development initiatives aimed at delivering cutting-edge solutions to their clients. As more organizations prioritize efficiency and accuracy in their screening endeavors, the competition within the HTS market is expected to intensify.

Among the prominent competitors in the market, Thermo Fisher Scientific Inc. stands out as a leading provider of high throughput screening technologies. The company offers a comprehensive range of instruments, reagents, and software solutions designed to facilitate efficient screening processes. With a strong focus on research and development, Thermo Fisher is continuously innovating its product offerings to address evolving market needs. Similarly, PerkinElmer, Inc. has established itself as a key player by providing advanced screening systems and solutions tailored for various applications, including drug discovery and toxicology assessment. The company’s commitment to enhancing research capabilities has solidified its position in the HTS market.

F. Hoffmann-La Roche AG is another significant competitor in the high throughput screening market, particularly known for its contributions to pharmaceutical research and development. The company leverages its expertise in drug discovery to offer robust HTS solutions that streamline the identification of novel therapeutic candidates. Moreover, Merck KGaA is actively involved in the HTS market, focusing on providing innovative technologies and services that enable researchers to navigate complex biological systems. These companies, along with others listed, are expected to play crucial roles in the ongoing evolution of the HTS market, driving advancements and fostering collaborations that will shape the future of drug discovery and development.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Merck KGaA
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Sartorius AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 BD Biosciences
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Lonza Group AG
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 PerkinElmer, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Epic Sciences, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Corning Incorporated
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Biotechne Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 DiscoverX Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 F. Hoffmann-La Roche AG
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Agilent Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Bio-Rad Laboratories, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 HighRes Biosolutions, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Thermo Fisher Scientific Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Charles River Laboratories International, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 High Throughput Screening (HTS) Market, By Product
    • 6.1.1 Instruments
    • 6.1.2 Reagents & Kits
    • 6.1.3 Consumables
    • 6.1.4 Software
    • 6.1.5 Services
  • 6.2 High Throughput Screening (HTS) Market, By End User
    • 6.2.1 Pharmaceutical and Biotechnology Companies
    • 6.2.2 Contract Research Organizations
    • 6.2.3 Academic and Research Institutes
    • 6.2.4 Others
  • 6.3 High Throughput Screening (HTS) Market, By Technology
    • 6.3.1 Label-Free Technology
    • 6.3.2 Cell-Based Assays
    • 6.3.3 Ultra High-Throughput Screening
    • 6.3.4 Lab-On-A-Chip Technology
    • 6.3.5 Others
  • 6.4 High Throughput Screening (HTS) Market, By Application
    • 6.4.1 Drug Discovery
    • 6.4.2 Toxicology Assessment
    • 6.4.3 Chemical Biology
    • 6.4.4 Biochemical Screening
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 High Throughput Screening (HTS) Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global High Throughput Screening (HTS) market is categorized based on

By Technology

• Label-Free Technology
• Cell-Based Assays
• Ultra High-Throughput Screening
• Lab-On-A-Chip Technology
• Others

By Application

• Drug Discovery
• Toxicology Assessment
• Chemical Biology
• Biochemical Screening
• Others

By End User

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Academic and Research Institutes
• Others

By Product

• Instruments
• Reagents & Kits
• Consumables
• Software
• Services

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Thermo Fisher Scientific Inc.
• PerkinElmer, Inc.
• Agilent Technologies, Inc.
• F. Hoffmann-La Roche AG
• Merck KGaA
• BD Biosciences
• Sartorius AG
• HighRes Biosolutions, Inc.
• Lonza Group AG
• Corning Incorporated
• Epic Sciences, Inc.
• Charles River Laboratories International, Inc.
• DiscoverX Corporation
• Bio-Rad Laboratories, Inc.
• Biotechne Corporation